Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BPTSNASDAQ:GOVXNASDAQ:NXTCNASDAQ:RLYB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBPTSBiophytis$13.37$8.05▼$168.80$2.89M1.057,291 shs18,500 shsGOVXGeoVax Labs$0.94+2.1%$1.00$0.73▼$11.18$14.34M3.451.21 million shs2.90 million shsNXTCNextCure$0.47+3.8%$0.46$0.22▼$1.82$13.18M1.07125,105 shs163,947 shsRLYBRallybio$0.31-6.0%$0.32$0.22▼$1.60$12.75M-1.24123,196 shs237,361 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBPTSBiophytis0.00%0.00%0.00%0.00%0.00%GOVXGeoVax Labs0.00%-8.35%-7.45%-27.94%-50.32%NXTCNextCure0.00%-30.98%-5.45%-17.54%-64.39%RLYBRallybio0.00%-5.40%-7.12%-54.25%-78.11%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBPTSBiophytisN/AN/AN/AN/AN/AN/AN/AN/AGOVXGeoVax Labs3.0925 of 5 stars3.64.00.00.02.51.70.6NXTCNextCure4.5091 of 5 stars3.55.00.04.31.71.71.3RLYBRallybio3.0382 of 5 stars3.05.00.00.00.01.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBPTSBiophytis 0.00N/AN/AN/AGOVXGeoVax Labs 3.29Buy$11.101,075.85% UpsideNXTCNextCure 3.00Buy$3.50644.68% UpsideRLYBRallybio 2.00Hold$10.003,162.64% UpsideCurrent Analyst Ratings BreakdownLatest BPTS, RLYB, GOVX, and NXTC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/16/2025GOVXGeoVax LabsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.005/2/2025GOVXGeoVax LabsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$14.00 ➝ $9.004/16/2025GOVXGeoVax LabsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.004/15/2025GOVXGeoVax LabsAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $8.504/15/2025RLYBRallybioJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold4/13/2025RLYBRallybioEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/10/2025GOVXGeoVax LabsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.00 ➝ $18.004/9/2025RLYBRallybioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral4/8/2025RLYBRallybioCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold3/28/2025GOVXGeoVax LabsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.00 ➝ $18.00(Data available from 6/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBPTSBiophytisN/AN/AN/AN/A($17.29) per shareN/AGOVXGeoVax Labs$3.95M3.63N/AN/A$0.48 per share1.97NXTCNextCureN/AN/AN/AN/A$2.34 per shareN/ARLYBRallybio$640K19.93N/AN/A$1.49 per share0.21Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBPTSBiophytis-$18.43MN/A0.00N/AN/AN/AN/AN/AN/AGOVXGeoVax Labs-$24.99M-$3.65N/AN/AN/A-438.20%-511.96%-286.58%8/5/2025 (Estimated)NXTCNextCure-$55.65M-$1.76N/AN/AN/AN/A-70.16%-58.10%7/30/2025 (Estimated)RLYBRallybio-$57.78M-$1.09N/AN/AN/A-5,682.19%-72.31%-64.78%8/14/2025 (Estimated)Latest BPTS, RLYB, GOVX, and NXTC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025RLYBRallybio-$0.21-$0.21N/A-$0.21N/A$0.21 million5/1/2025Q1 2025GOVXGeoVax Labs-$0.59-$0.45+$0.14-$0.45$0.75 million$1.64 million5/1/2025Q1 2025NXTCNextCure-$0.40-$0.39+$0.01-$0.39N/AN/A3/27/2025Q4 2024GOVXGeoVax Labs-$0.79-$0.30+$0.49-$0.30$2.38 million$3.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBPTSBiophytisN/AN/AN/AN/AN/AGOVXGeoVax LabsN/AN/AN/AN/AN/ANXTCNextCureN/AN/AN/AN/AN/ARLYBRallybioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBPTSBiophytisN/A0.720.72GOVXGeoVax LabsN/A3.623.62NXTCNextCureN/A10.2610.26RLYBRallybioN/A14.6814.68Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBPTSBiophytis0.05%GOVXGeoVax Labs6.09%NXTCNextCure42.65%RLYBRallybio90.34%Insider OwnershipCompanyInsider OwnershipBPTSBiophytis3.70%GOVXGeoVax Labs1.20%NXTCNextCure17.90%RLYBRallybio8.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBPTSBiophytis22351,000338,000Not OptionableGOVXGeoVax Labs1015.19 million15.01 millionNot OptionableNXTCNextCure9028.05 million23.03 millionOptionableRLYBRallybio4041.61 million37.99 millionNot OptionableBPTS, RLYB, GOVX, and NXTC HeadlinesRecent News About These CompaniesRallybio Initiates Dosing in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic StudyJune 13, 2025 | finance.yahoo.comRallybio’s SWOT analysis: C5 inhibitor focus shifts stock outlookMay 24, 2025 | investing.comRallybio shareholders elect directors, ratify auditorMay 18, 2025 | uk.investing.comRallybio Reports First Quarter 2025 Financial Results and Provides Business UpdatesMay 9, 2025 | finance.yahoo.comRallybio to Present at the 2025 Citizens JMP Life Sciences ConferenceApril 29, 2025 | finance.yahoo.comJones Trading Downgrades Rallybio (RLYB)April 15, 2025 | msn.comRallybio downgraded to Hold from Buy at JonesResearchApril 14, 2025 | markets.businessinsider.comRallybio downgraded to In Line from Outperform at Evercore ISIApril 12, 2025 | markets.businessinsider.comRallybio (RLYB) was downgraded to a Hold Rating at H.C. WainwrightApril 10, 2025 | markets.businessinsider.comRallybio Stock Short Interest Report | NASDAQ:RLYB | BenzingaApril 9, 2025 | benzinga.comRallybio discontinues RLYB212 programApril 9, 2025 | markets.businessinsider.comRallybio sinks as it drops RLYB212 for prevention of FNAITApril 9, 2025 | thepharmaletter.comHC Wainwright & Co. Downgrades Rallybio (RLYB)April 9, 2025 | msn.comRLYB Ends Pregnancy-Related Rare Disease Program, Stock TanksApril 9, 2025 | zacks.comCitizens JMP downgrades Rallybio on RLYB212 discontinuationApril 9, 2025 | markets.businessinsider.comJMP Securities downgrades Rallybio (RLYB) to a HoldApril 9, 2025 | theglobeandmail.comRallybio Stock Plunges After Program For Pediatric Bleeding Disorder DisappointsApril 8, 2025 | benzinga.comRallybio Discontinues Development of Treatment for Prevention of Rare Immune DisorderApril 8, 2025 | marketwatch.comRallybio to Discontinue Development of RLYB212 for Prevention of FNAITApril 8, 2025 | finance.yahoo.comRallybio reports Q4 EPS (25c), consensus (30c)March 13, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBPTS, RLYB, GOVX, and NXTC Company DescriptionsBiophytis NASDAQ:BPTSBiophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses including inflammatory, oxidative, metabolic, and viral stresses that lead to age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.GeoVax Labs NASDAQ:GOVX$0.94 +0.02 (+2.09%) As of 06/20/2025 04:00 PM EasternGeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; other infectious disease vaccines for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.NextCure NASDAQ:NXTC$0.47 +0.02 (+3.84%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$0.48 +0.01 (+1.91%) As of 06/20/2025 06:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.Rallybio NASDAQ:RLYB$0.31 -0.02 (-6.01%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$0.32 +0.01 (+4.08%) As of 06/20/2025 06:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes Marvell's New AI Chip Deals Capture Wall Street’s Attention Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer GE Aerospace Turns Engines Into Long-Term Profits 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
